What 8 Analyst Ratings Have To Say About Surgery Partners

Aug 19, 2024 · Insights from analysts' 12-month price targets are revealed, presenting an average target of $42.25, a high estimate of $50.00, and a low estimate of $31.00. Observing a downward trend, the ...

CouponFollow Extension

$42.25
OFF

What 8 Analyst Ratings Have To Say About Surgery Partners

1 week from now

nasdaq.com

$40.13
OFF

Surgery Partners (SGRY) Stock Forecast And Price Target 2024

1 week from now

5 days ago · According to the 9 analysts' twelve-month price targets for Surgery Partners, the average price target is $40.13. The highest price target for SGRY is $50.00, while the lowest …

marketbeat.com

$44.44
OFF

9 Analysts Assess Surgery Partners: What You Need To Know

1 week from now

Oct 4, 2024 · Analysts have recently evaluated Surgery Partners and provided 12-month price targets. The average target is $44.44, accompanied by a high estimate of $50.00 and a low …

nasdaq.com

$43
OFF

Decoding 9 Analyst Evaluations For Surgery Partners

1 week from now

Nov 4, 2024 · 0. 0. 0. The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $43.0, a high estimate of $50.00, and a low estimate of $35.00. …

benzinga.com

$40
OFF

Critical Insights From Surgery Partners Analyst Ratings: What You …

1 week from now

Jun 28, 2024 · In the assessment of 12-month price targets, analysts unveil insights for Surgery Partners, presenting an average target of $40.5, a high estimate of $50.00, and a low estimate …

businessinsider.com

$44.73
OFF

Surgery Partners (NASDAQ:SGRY) Stock, Analyst Ratings, Price …

1 week from now

Surgery Partners Inc has a consensus price target of $44.73 based on the ratings of 16 analysts. The high is $73 issued by Barclays on November 30, 2021. The low is $35 issued by …

benzinga.com

14%
OFF

Jefferies Cuts Surgery Partners Target To $40, Maintains Buy Rating

1 week from now

5 days ago · In other recent news, Surgery Partners reported a robust third quarter in 2024, with net revenue climbing 14% year-over-year to $770 million. The company's adjusted EBITDA …

investing.com

$49.12
OFF

8 Analysts Have This To Say About MPLX - Benzinga

1 week from now

3 days ago · Analysts have set 12-month price targets for MPLX, revealing an average target of $49.12, a high estimate of $55.00, and a low estimate of $43.00.

benzinga.com

$50.19
OFF

What 16 Analyst Ratings Have To Say About Maplebear

1 week from now

4 days ago · Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $50.19, with a high estimate of $60.00 and a low estimate of $41.00.

nasdaq.com

$25
OFF

What 4 Analyst Ratings Have To Say About Adient - Benzinga

1 week from now

4 days ago · In the assessment of 12-month price targets, analysts unveil insights for Adient, presenting an average target of $25.0, a high estimate of $30.00, and a low estimate of $19.00.

benzinga.com

FAQs about What 8 Analyst Ratings Have To Say About Surgery Partners Coupon?

How do analysts evaluate Surgery Partners's stock?

Price Targets: Delving into movements, analysts provide estimates for the future value of Surgery Partners's stock. This analysis reveals shifts in analysts' expectations over time. For valuable insights into Surgery Partners's market performance, consider these analyst evaluations alongside crucial financial indicators. ...

Is Surgery Partners a good stock to buy?

The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings. According to analysts' consensus price target of $45.13, Surgery Partners has a forecasted upside of 41.1% from its current price of $31.99. Surgery Partners has only been the subject of 2 research reports in the past 90 days. ...

How did Surgery Partners (SGRY) perform in the quarter?

Surgery Partners, Inc. (NASDAQ:SGRY) released its quarterly earnings data on Tuesday, November, 7th. The company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.10 by $0.05. The business had revenue of $674.10 million for the quarter, compared to analyst estimates of $670.74 million. ...

How did surgery partners perform compared to consensus expectations?

Despite a slight miss in adjusted EPS compared to consensus expectations, Surgery Partners demonstrated strong year-over-year growth in adjusted EBITDA, which slightly exceeded projections. The firm’s consolidated revenue also surpassed expectations, indicating robust operational performance. ...

What if surgery partners' net margin is -1.73%?

With a net margin of -1.73%, the company may face hurdles in effective cost management. Return on Equity (ROE): Surgery Partners's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -0.63%, the company may encounter challenges in delivering satisfactory returns for shareholders. ...

Does Surgery Partners have a good return on equity (ROE)?

Return on Equity (ROE): Surgery Partners's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.05%, the company showcases efficient use of equity capital and strong financial health. ...